NEW YORK — Bioké, a Dutch developer of cell signaling technologies, said on Thursday that it has signed an agreement with Applied Cells to distribute that firm's MARS cell isolation and separation instrument in the Netherlands, Belgium, and Luxembourg.
Financial and other terms of the deal were not disclosed.
MARS — short for multi-physics automated reconfigurable separation — uses active-microfluidic acoustics and magnetic separation technologies to isolate and recover targeted cells from whole blood, apheresis, and bone marrow samples, according to Applied Cells.
The instrument "will allow [Bioké customers] to identify rare populations for diagnostic markers and potentially isolate new cellular therapeutics," Bioké Sales Manager Robert Hovingh said in a statement. "We are very excited about the opportunities this technology will enable for cell therapy, tumor biology, and genomics research in the Benelux."
Last month, Santa Clara, California-based Applied Cells struck a deal with S2 Genomics to jointly market its MARS technologies with S2 Genomics' Singulator 100 solid tissue dissociation system.